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Summary
Nasopharyngeal cancer is
highly treatable with radia-
tion therapy, but the treat-
ment outcome varies widely
across the world. Eighty
percent of new cases
occurred in countries with
poor outcome. This study
showed a signiﬁcant corre-
lation between outcome and
access to radiation therapy.
The global inequity of access
and the need for optimal
service planning are high-
lighted. It is hoped that this
work will help stimulate an
international effort toward
improving the outcome for
nasopharyngeal cancer
worldwide.
Objective: This study aimed to estimate the treatment outcome of nasopharyngeal
cancer (NPC) across the world and its correlation with access to radiation therapy
(RT).
Methods and Materials: The age-standardized mortality (ASM) and age-standardized
incidence (ASI) rates of NPC from GLOBOCAN (2012) were summarized, and [1
(ASM/ASI)] was computed to give the proxy relative survival (RS). Data from
the International Atomic Energy Agency (IAEA) and the World Bank were used to
assess the availability of RT in surrogate terms: the number of RT equipment units
and radiation oncologists per million population.
Results: A total of 112 countries with complete valid data were analyzed, and the
proxy RS varied widely from 0% to 83% (median, 50%). Countries were categorized
into Good, Median, and Poor outcome groups on the basis of on their proxy RS
(<45%, 45%-55%, and >55%). Eighty percent of new cases occurred in the Poor
outcome group. Univariable linear regression showed a signiﬁcant correlation between
outcome and the availability of RT: proxy RS increased at 3.4% (P<.001) and 1.5%
(PZ.001) per unit increase in RT equipment and oncologist per million population,
respectively. The median number of RT equipment units per million population
increased signiﬁcantly from 0.5 in the Poor, 1.5 in the Median, to 4.6 in the Good
outcome groups, and the corresponding number of oncologists increased from 1.1,
3.3 to 7.1 (P<.001).
Conclusions: Nasopharyngeal cancer is a highly treatable disease, but the outcome
varies widely across the world. The current study shows a signiﬁcant correlation
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between survival and access to RT based on available surrogate indicators. However,
the possible reasons for poor outcome are likely to be multifactorial and complex.
Concerted international efforts are needed not only to address the fundamental require-
ment for adequate RT access but also to obtain more comprehensive and accurate data
for researches to improve cancer outcome.  2015 Elsevier Inc. All rights reserved.
Introduction
Epidemiologic data from GLOBOCAN by the International
Agency for Research on Cancer (IARC) showed that the
total number of new cases of nasopharyngeal cancer (NPC)
in the world was 86,691 and the total number of deaths was
50,831 in the year 2012 (1). This cancer has a skewed
geographic distribution: 81% of new cases occurred in Asia
and 9% in Africa. In terms of the actual number of new
patients, the top 5 countries were China, Indonesia, Viet-
nam, India, and Malaysia, which together accounted for
67% of the global burden (Fig. 1).
This cancer was invariably lethal in the past before the
advent of megavoltage radiation therapy (RT). Access to
good-quality RT is a fundamental need for treating NPC;
with accumulation of knowledge, advancing technology for
accurate delineation of disease extent and irradiation
techniques, and the addition of potent chemotherapy, 5-year
survival rates >80% can now be achieved for patients
treated in major centers (2).
There is marked variation in the availability of RT fa-
cilities and the quality of service among different countries.
The capital and expertise required for providing a proper
RT infrastructure represent a major health challenge in low-
income and middle- income countries (LMICs). A study by
Datta et al (3) showed that only one third of the global
teletherapy units exist in LMICs to treat nearly 60% of the
world’s cancer patients. Published articles analyzing access
to RT in different regions mostly estimate the needs based
on the number of cancer cases and RT utilization rates, or
comparison of available RT resources against benchmarks
(4, 5). The current study is the ﬁrst attempt to link RT ac-
cess with survival outcome, using NPC as an example Q1.
Methods and Materials
Estimation of survival outcome
Most of the cancer registries in countries where NPC is
prevalent do not have detailed individual patient records
with prospective follow-up data. The best available in-
dicators of the disease burden in each country are the age-
standardized mortality (ASM) and age-standardized
incidence (ASI) rates from GLOBOCAN 2012 (1). Inas-
much as a previous study has shown that [1(ASM/ASI)] is
a good approximation of the 5-year relative survival (RS)
for most tumor sites (6), this was used to compute a proxy
RS for comparison of treatment outcomes among different
countries.
Information on access to radiation therapy
Information on the availability of RT facilities and
personnel in different countries was retrieved from the




















































Fig. 1. Epidemiologic pattern of nasopharyngeal cancer: total number of new patients and deaths by countries. (Data from
GLOBOCAN 2012).
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Atomic Energy Agency (IAEA-DIRAC) (7). The total
populations of different countries in 2012 were retrieved
from The World Bank database (8). Two surrogate in-
dicators were calculated to reﬂect the access to RT: the
number of RT equipment units (linear accelerators, cobalt
units, or both) and the number of radiation oncologists per
million population.
Inclusion and exclusion criteria
Countries in each continent (Asia, Africa, America,
Europe, and Oceania) were identiﬁed; all those with com-
plete ASM, ASI, equipment, oncologist, and population
data were reviewed. Countries without RT facilities and
gross outliers with concern about the quality of epidemio-
logic data (ASM/ASI ratio equal to zero or exceed 1) were
excluded from the analysisQ2 .
Statistical analysis
To evaluate the correlation of survival outcome with RT
facilities and personnel, univariable linear regression was
performed with proxy RS as the dependent variable, and RT
equipment and oncologists as independent variables sepa-
rately. The coefﬁcients of determination (R2) and the
regression coefﬁcients (b) were measured. In addition,
countries were divided into 3 outcome groups (Poor, Me-
dian, and Good) based on the proxy RS, and the medians of
the RT indicators between the groups were compared by
Mood’s median test. All statistical analysis was performed
with IBM SPSS Statistics 20.0.
Results
Of the 128 countries with complete data on RT indicators,
16 outliers were excluded because of concern about the
quality of epidemiologic data (proxy RS less than 0% or
equal to 100%). A total of 112 countries with complete
valid data (33 from Asia, 21 from Africa, 22 from America,
34 from Europe, and 2 from Oceania) were included in the
current analyses. The total number of new patients in these
countries was 82,127 (95% of the global burden).
The outcomes varied widely among countries: the proxy
RS ranged from 0% to 83% (median, 50%). When a proxy
RS of 45% to 55% was taken as an average achievement,
countries could be categorized into Poor, Median, and
Good outcome groups based on proxy RS <45%, 45% to
55%, and >55%, respectively (Table 1). Different conti-
nents showed different proportions of countries categorized
into the 3 groups: only 18% (6/33) of countries in Asia and
5% (1/21) in Africa had Good outcome compared with 53%
(18/34) in Europe.
Inasmuch as most of the countries with Poor outcome
had a high incidence of NPC, the total number of new
patients in the Poor outcome group was 69,012 (80% of the
global burden). Among the 48 countries with Poor
outcome, the 14 countries with incidence >500 new pa-
tients in the year 2012 already accounted for 75% of the
global burden (Table 2).
The availability of RT varied widely across the world:
the number of RT equipment units ranged from 0.02 to 12.6
(mean, 2.6; median, 1.6) per million population; 63 coun-
tries (56%) had <2 RT equipment units per million popu-
lation. The number of radiation oncologists ranged from
Table 1 Summary of different outcome groups
Outcome groups
PPoor Median Good
Total no. of new cases 69,012 4599 8516
Proxy relative survival
Range 0-43.8% 5.5-52.6% 55.6-83.3%
Mean  SD 20.5  15.6% 49.6  1.4% 66.3  8.0%
Median 25% 50% 66.7%
Continent, countries <.001
Asia 14 13 6
Africa 16 4 1
America 8 9 5
Europe 10 6 18
Oceania 0 1 1
All 48 33 31
Equipment/million <.001
Mean  SD 1.12  1.66 2.45  2.23 4.93  2.81
Median 0.50 1.49 4.56
Oncologists/million <.001
Mean  SD 2.77  3.86 4.68  4.40 7.84  4.47
Median 1.05 3.32 7.14
Abbreviation: SD Z standard deviation.
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0.03 to 20.5 (mean, 4.7 median, 3.2) per million population.
There were 55 countries (49%) with <3 radiation oncolo-
gists per million population.
Univariable linear regression showed a statistically sig-
niﬁcant correlation between proxy RS and both RT access
indicators (Fig. 2): a unit increase in RT equipment per
million population was associated with an absolute increase
of 3.4% (95% conﬁdence interval [CI], 1.97-4.88) in proxy
RS (P<.001, R2 Z .166), whereas a unit increase in on-
cologists per million population was associated with an
absolute increase of 1.5% (95% CI, 0.60-2.33) in proxy RS
(PZ.001, R2 Z .093).
There were signiﬁcant differences in RT facilities and
personnel among the 3 outcome groups (P<.001) (Fig. 3).
The median number of RT equipment units per million
population increased from 0.5 in the Poor, 1.5 in the Me-
dian, to 4.6 in the Good outcome groups; the corresponding
number of oncologists increased from 1.1, 3.3 to 7.1
(Table 1).
Discussion
Global surveillance of cancer survival is increasingly
advocated to stimulate health policy and reduce inequity (9,
10). GLOBOCAN 2012 by IARC of the World Health
Organization provides the best updated estimates of the
incidence, mortality, and prevalence of major cancer at a
national level (1). These data are useful for comparison of
cancer burden in different countries. However, it should be
noted that the quality of the estimation varies depending on
the availability of incidence and mortality data and the
methods of estimation used for each country.
Accurate calculation of cancer survival requires detailed
individual patient records with prospective follow-up data.
Unfortunately, most cancer registries (particularly those in
LMIC) cannot provide such data. The best possible surrogate
currently available for outcome estimation is [1(ASM/
ASI)]; as shown in the study by Vostakolaei et al (6) on 32
cancer sites in 7 different countries, this indicator is a good
approximation of 5-year relative survival for most sites.
It is well known that the overall outcome for cancer
patients in LMIC is substantially poorer than that achiev-
able in developed countries. The possible reasons for poor
outcome in any individual country are likely to be multi-
factorial and complex. However, the data for supporting a
more exact analysis of the effect of all possible factors from
cultural, geographic, and socioeconomic issues to all as-
pects of health care provision from diagnoses, staging, and
cancer treatment modalities to supportive care are lacking
and are unlikely to become available in the near future.
Of all these factors, inadequate access to RT facilities is
one of the key problems. It is worthwhile to start studying
this serious problem because RT is increasingly used as a
deﬁnitive treatment modality for many cancers, and the
setup of RT services involves comprehensive planning and
high capital cost. Currently, the only source of information
about RT access is the DIRAC-IAEA (7), which is a reg-
istry of the number of RT equipment and staff members in
different countries based on continuous update by member
states. However, it should be cautioned that the data are
based on voluntary reporting, and there is no information
on quality of RT (for example, the machine capability for
conformal/intensity-modulated techniques and quality
assurance). Furthermore, accurate comparison of stafﬁng
across countries is especially difﬁcult because of variations
in the scope of services by oncologists (conﬁned to radia-
tion oncology alone in some countries, but covering both
radiation and medical oncology in others). Concerned with
this pitfall, IAEA has suspended the release of stafﬁng in-
formation to the public, and efforts are now being taken to
address this issue.






Access to radiation therapy per
million population
New cases Deaths ASI ASM Equipment Oncologists
China 33,198 20,404 1.9 1.2 36.8 1.13 5.27
Indonesia 13,084 7391 5.6 3.3 41.1 0.16 0.17
Vietnam 4931 2885 5.4 3.3 38.9 0.42 1.26
India 3947 2836 0.4 0.3 25.0 0.42 0.29
Thailand 1864 1114 2.1 1.3 38.1 1.24 1.08
Philippines 1738 873 2.2 1.3 40.9 0.40 1.89
Myanmar 1148 785 2.4 1.8 25.0 0.13 0.44
Algeria 1083 548 3.2 1.8 43.8 0.49 0.88
Nigeria 1062 744 0.8 0.6 25.0 0.08 0.18
Pakistan 795 532 0.6 0.4 33.3 0.31 0.17
Kenya 784 500 3 2.1 30.0 0.14 0.25
Morocco 726 428 2.3 1.4 39.1 0.95 3.26
Tanzania 531 371 1.8 1.4 22.2 0.04 0.13
Sudan 531 400 2.3 1.8 21.7 0.27 0.51
Abbreviations: ASI Z Age-standardized incidence rate; ASM Z Age-standardized mortality rate; Proxy RS Z Proxy relative survival.
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Naturally, the RT facilities in a country are used for all
indicated cancers rather than a speciﬁc cancer, but for
analysis of the correlation between RT access and cancer
outcome, inclusion of all cancers is not adopted because
heterogeneity in the RT utilization rates. NPC is one of the
best cancers for analyzing the link because this is a highly
curable cancer and RT is the fundamental treatment
modality; the RT utilization rate is 100%, surgery is used
only for salvaging persistence/recurrence, and the absolute
magnitude of increase in 5-year overall survival by adding
chemotherapy is only 6% according to the latest meta-
analysis (11).
The current study showed a marked variation in outcome
of NPC among different countries: the proxy RS ranged
from 0% to 83%. Countries can be divided into Poor,
Median, and Good outcome groups on the basis of proxy
RS (Table 1); only 18% of countries in Asia and 5% in
Africa had proxy RS >55%. For the 48 countries in the
Poor outcome group, the median proxy RS was only 25%.
Most unfortunately, these countries are those with the
highest incidence of NPC; 69,012 new patients were
registered in these countries in the year 2012, accounting
for 80% of the global burden. The social consequences are
clearly enormous because the peak incidence occurs at 40
to 50 years of age in endemic countries.
100
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Fig. 2. Correlation of proxy relative survival with (A)
radiation therapy (RT) equipment and (B) radiation on-






































































Fig. 3. Comparison of radiation therapy (RT) access
indicators in different outcome groups. (A) RT equipment
and (B) radiation oncologists per million population.
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There is marked inequity of access to RTacross theworld:
the number of RTequipment rangedwidely from 0.02 to 12.6
per million population. The current study demonstrated a
strongly signiﬁcant correlation between access and outcome
(Table 1, Figs. 2 and 3). The median number of equipment
units was 0.5 in the Poor outcomegroup comparedwith 4.6 in
the Good outcome group. Similarly, the number of radiation
oncologists ranged widely from 0.03 to 20.5 per million
population: the correspondingmedian number of oncologists
was 1.1 in the Poor outcome group compared with 7.1 in the
Good outcome group. Improvement of access to RT is a
fundamental issue to be addressed for helping the Poor
outcome countries.
This study is the ﬁrst attempt to link RT access with
survival outcome. Although there are limitations because
the current ﬁndings are based on surrogate indicators and
other confounding factors affect outcome, nevertheless, this
attempt provides a vivid example to reﬂect the current
unfortunate situation in LMIC. Furthermore, this could
contribute to a call for more comprehensive international
data and stimulate global health research to develop sus-
tainable health policy for improving cancer care.
Besides the problem of access, the quality of RT and the
overall pattern of care are also important. There are wide
variations in treatment results achieved by different centers.
This is highlighted by a prospective randomized trial con-
ducted by IAEA, which aimed to evaluate the addition of a
brachytherapy boost in patients with advanced NPC treated
by standard chemoradiation therapy (12). A total of 274
patients from participating centers in Egypt, Algeria,
Morocco, Pakistan, and Thailand during the period 2004 to
2008 were studied. The 3-year results showed no signiﬁcant
improvement in local failure-free survival by adding
brachytherapy. The key concern was that local control was
poor even in patients with T1-2Nþ disease (58% with
brachytherapy vs 52% without brachytherapy, PZ.34).
Reports from a center at Yogyakarta in Indonesia, the
country with the second largest number of new NPC
patients, revealed even more disturbing ﬁndings: the com-
plete response achieved for NPC patients was only 29%,
and the median overall survival was less than 2 years (13).
A detailed analysis of patients treated with curative RT
from 2011 to 2012 showed that long diagnosis-to-treatment
intervals and prolongation of overall treatment time were
the major contributory factors to the poor treatment out-
comes (14). The main causes of the prolongation included
malfunctioning equipment, modiﬁcation of radiation ﬁelds,
public holidays, power blackout, and patients’ poor con-
dition or preference. These illustrate the multifactorial na-
ture of difﬁculties leading to poor outcomes at centers in
LMIC.
Even in centers from developed countries, the impor-
tance of the quality of RT cannot be overemphasized. A
corollary ﬁnding in the TROG 02.02 (HeadSTART) Trial,
which aimed to evaluate the therapeutic beneﬁt of tira-
pazamine for advanced head and neck carcinoma, showed
that patients with major deﬁciencies in their treatment plans
had a markedly inferior outcome than did patients whose
treatment was protocol compliant: the 2 years overall sur-
vival was 50% versus 70%, and the locoregional failure-
free rate was 54% versus 78% (PZ.001) (15).
Another important factor is the overall pattern of care
from diagnosis to completion of therapy. Experience from
Hong Kong demonstrates a steady improvement in outcome
with evolving advances (Table 3), as shown by 3 repre-
sentative studies during different periods (2, 16, 17). The
increasing use of more accurate staging investigation by
magnetic resonance imaging and positron emission to-
mography, more conformal RT using the intensity-
modulated technique, optimal dose fractionation, and the
addition of concurrent  sequential chemotherapy for pa-
tients with locoregionally advanced disease all contributed
to achieving the contemporary best results. The most
encouraging message is that a 5-year survival of 50% is
achievable even with staging by x-ray and treatment by 2-
dimensional RT alone. This highlights the importance of
other contributory improvements and the results achievable
within the limitation of resources as our services evolve.
The current analysis has started to attract international
interest. The IAEA is now launching a coordinated research
project to improve the outcomes of NPC in LMIC. The 14
countries with Poor outcome and moderate to high
Table 3 Summary of results from 3 representative studies in Hong Kong
Study Year
Staging investigation Stage* RT technique
Total dose
Chemotherapy 5-year





1976-1980 100% 0.1% 0 0 72% 100% 0 0 81% > 60 Gy 0 7% 47%
1981-1985 72% 28% 0 0 73% 100% 0 0 91% > 60 Gy 0 11% 57%
Lee et al,
2005 (17)
1996-2000 0 100% 0 0 47% 96% 4% 0 4% > 66 Gy 9% 10% 79%
0 0 100% 0 65% 78% 22% 0 49% > 66 Gy 23% 9% 83%
Lee, 2014 (8)Q3 1994-1998 0 84% 16% 0 59% 100% 0 0 All 66 Gy 20% 16% 78%
1998-2005 0 2% 98% 0.3% 85% 0 100% 0 All 70 Gy 55% 3% 81%
2005-2010 0 0 100% 25% 92% 0 0 100% All 70 Gy 87% 2% 85%
Abbreviations: CT Z computed tomography; DSS Z disease-speciﬁc survival; IMRT Z intensity-modulated radiotherapy; MRI Z magnetic reso-
nance imaging; PET Z positron emission tomography; RT Z radiation therapy.
* Stage by AJCC/UICC, 5th edition.





























































































































FLA 5.4.0 DTD  ROB23298_proof  5 January 2016  12:26 pm  ce AC
incidence (Table 2) will be the key targets for improvement
because 75% of global new patients occur in these coun-
tries. The project will include a national survey for more
comprehensive data of RT facilities, a cross-sectional study
on patient characteristics, the pattern of care, the quality of
RT planning and clinical outcome in representative centers,
and a comparative study to explore for outcome improve-
ment by educational intervention and the establishment of
quality review processes. It is hoped these international
efforts can help to stimulate government in Poor outcome
countries to improve service provisions and less experi-
enced centers to improve their quality of RT so that the
maximum number of patients can be cured.
It is concluded that NPC is highly curable, but the out-
comes varied widely; unfortunately, 80% of patients with
new diagnoses were in LMIC with poor outcome (proxy RS
<45%), The current study is the ﬁrst attempt to correlate
the outcome with RT resources based on available surrogate
indicators (proxy survival from data by GLOBOCAN 2012,
number of external RT equipment and radiation oncologists
from IAEA-DIRAC). It is important to start studying the
serious problem of RT access because this is a fundamental
requirement; the setup of RT services involves compre-
hensive planning and high capital cost. There is little doubt
that outcome could also be affected by other confounding
factors, but the data necessary for supporting a more exact
analysis of the effect of all possible factors are currently
unavailable. This report is a starting step to call for
concerted international efforts to address not only the
inequity of RT access in LMIC but also the need for more
comprehensive and more accurate data for health care
research, to draw the attention of policy makers to develop
sustainable health policy for improving cancer care.
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